Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Roeland E Wasmann; Cornelis Smit; Eric P H van Dongen; René M J Wiezer; Jill Adler-Moore; Yvo M de Beer; David M Burger; Catherijne A J Knibbe; Roger J M Brüggemann

doi:10.1093/cid/ciz885

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Clin Infect Dis. 2020 May 6;70(10):2213-2215. doi: 10.1093/cid/ciz885.

Authors

Roeland E Wasmann^{1

2}, Cornelis Smit^{3

4}, Eric P H van Dongen⁵, René M J Wiezer⁶, Jill Adler-Moore⁷, Yvo M de Beer⁸, David M Burger¹, Catherijne A J Knibbe^{3

4}, Roger J M Brüggemann^{1

2}

Affiliations

¹ Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nieuwegein, The Netherlands.
² Center of Expertise in Mycology Radboudumc/Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
³ Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.
⁴ Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
⁵ Department of Anesthesiology, Intensive Care and Pain Management, St. Antonius Hospital, Nieuwegein, The Netherlands.
⁶ Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
⁷ Department of Biological Sciences, California State Polytechnic University, Pomona, California.
⁸ Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands.

Abstract

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

Keywords: fungal infection; fungal treatment; obese; optimal dosing; population pharmacokinetics.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Amphotericin B
Antifungal Agents* / therapeutic use
Humans
Obesity, Morbid* / complications
Obesity, Morbid* / drug therapy
Prospective Studies

Substances

Antifungal Agents
liposomal amphotericin B
Amphotericin B

Associated data

ClinicalTrials.gov/NCT02320604